$0.380
+0.005 (+1.31%)Al cierre
Noticias de TPST
Eventos de TPST
Selling Stockholders Plan to Sell 9.53M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 9.53M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Tempest Therapeutics Appoints Nancy Freda-Smith to Board of Directors
Tempest Therapeutics announced that Nancy Freda-Smith has been appointed to its board of directors and will serve as Chair of the Audit Committee.
Tempest Therapeutics Enters Exclusive Option Agreement with Hebei Senlang Biotechnology
Tempest Therapeutics announced that it has entered into an exclusive option agreement with Hebei Senlang Biotechnology. The agreement provides Tempest with an exclusive option to license Senlang's CD7-targeted lentiviral vector platform and a portfolio of in vivo CAR-T product candidates. The portfolio includes a BCMA/GPRC5D dual-targeting in vivo CAR-T candidate currently in Phase 1 dose escalation for relapsed/refractory multiple myeloma, as well as additional candidates for hematologic malignancies and autoimmune diseases. The candidate is currently being evaluated in an ongoing Phase 1 dose-escalation study in patients with relapsed/refractory multiple myeloma.
Tempest Therapeutics Completes Private Placement of 3.1 Million Shares
Tempest Therapeutics announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,105,591 shares of common stock, series C warrants to purchase up to 3,105,591 shares of common stock and series D warrants to purchase up to 3,105,591 shares of common stock, at a combined purchase price of 80.5c per share of common stock and accompanying warrants in a private placement. The series C warrants and the series D warrants will have an exercise price of 80.5c per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants. The series C warrants will expire six years from the later of the Stockholder Approval Date and the Effectiveness Date and the series D warrants will expire three years from the later of the Stockholder Approval Date and the Effectiveness Date. The private placement is expected to close on or about September 14, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Selling Stockholders Plan to Sell Up to 8.91M Shares
This filing relates to the offer and sale from time to time by the selling stockholders of up to 8.91M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Artículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.